Intrarenal delivery of bFGF-loaded liposome under guiding of ultrasound-targeted microbubble destruction prevent diabetic nephropathy through inhibition of inflammation

References

• Kanwar YS, Wada J, Sun L, et al. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood). 2008;233:4–11.
   PubMed Web of Science ®Google Scholar
• Luis-Rodriguez D, Martínez-Castelao A, Górriz JL, et al. Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy. Wjd. 2012;3:7–18.
   Google Scholar
• Rivero A, Mora C, Muros M, et al. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin Sci. 2009;116:479–492.
   PubMed Web of Science ®Google Scholar
• Tesch GH. Macrophages and diabetic nephropathy. Semin Nephrol. 2010;30:290–301.
   PubMed Web of Science ®Google Scholar
• Sanchez-Nino MD, Bozic M, Córdoba-Lanús E, et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol. 2012;302:F647–F657.
   PubMed Web of Science ®Google Scholar
• Wu J, Guan TJ, Zheng S, et al. Inhibition of inflammation by pentosan polysulfate impedes the development and progression of severe diabetic nephropathy in aging C57B6 mice. Lab Invest. 2011;91:1459–1471.
   PubMed Web of Science ®Google Scholar
• Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009;27:693–733.
   PubMed Web of Science ®Google Scholar
• Palsamy P, Subramanian S. Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim Biophys Acta. 2011;1812:719–731.
   PubMed Web of Science ®Google Scholar
• Pai S, Thomas R. Immune deficiency or hyperactivity-Nf-kappab illuminates autoimmunity. J Autoimmun. 2008;31:245–251.
   PubMed Web of Science ®Google Scholar
• Ahad A, Ganai AA, Mujeeb M, et al. Ellagic acid, an NF-kappaB inhibitor, ameliorates renal function in experimental diabetic nephropathy. Chem Biol Interact. 2014;219:64–75.
   PubMed Web of Science ®Google Scholar
• Navarro-Gonzalez JF, Mora-Fernández C, Muros de Fuentes M, et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011;7:327–340.
   PubMed Web of Science ®Google Scholar
• Nogueira-Machado JA, Volpe CM, Veloso CA, et al. HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation. Expert Opin Ther Targets. 2011;15:1023–1035.
   PubMed Web of Science ®Google Scholar
• Yasuda-Yamahara M, Kume S, Tagawa A, et al. Emerging role of podocyte autophagy in the progression of diabetic nephropathy. Autophagy. 2015;11:2385–2386.
   PubMed Web of Science ®Google Scholar
• Li S, Liu X, Lei J, et al. Crocin protects podocytes against oxidative stress and inflammation induced by high glucose through inhibition of NF-kappaB. Cell Physiol Biochem. 2017;42:1481–1492.
   PubMed Web of Science ®Google Scholar
• Economou CG, Kitsiou PV, Tzinia AK, et al. Enhanced podocalyxin expression alters the structure of podocyte basal surface. J Cell Sci. 2004;117:3281–3294.
   PubMed Web of Science ®Google Scholar
• Ingaramo PI, Ronco MT, Francés DE, et al. Tumor necrosis factor alpha pathways develops liver apoptosis in type 1 diabetes mellitus. Mol Immunol. 2011;48:1397–1407.
   PubMed Web of Science ®Google Scholar
• Villanueva S, Cespedes C, Gonzalez A, et al. bFGF induces an earlier expression of nephrogenic proteins after ischemic acute renal failure. Am J Physiol Regul Integr Comp Physiol. 2006;291:R1677–R1687.
   PubMed Web of Science ®Google Scholar
• Tan XH, Zheng XM, Yu LX, et al. Fibroblast growth factor 2 protects against renal ischaemia/reperfusion injury by attenuating mitochondrial damage and proinflammatory signalling. J Cell Mol Med. 2017;21:2909–2925.
   PubMed Web of Science ®Google Scholar
• Villanueva S, Contreras F, Tapia A, et al. Basic fibroblast growth factor reduces functional and structural damage in chronic kidney disease. Am J Physiol Renal Physiol. 2014;306:F430–F441.
   PubMed Web of Science ®Google Scholar
• Lin X, Zhao L, Tang S, et al. Metabolic effects of basic fibroblast growth factor in streptozotocin-induced diabetic rats: a (1)H NMR-based metabolomics investigation. Sci Rep. 2016;6:36474.
   PubMed Web of Science ®Google Scholar
• Zhao YZ, Zhang M, Tian XQ, et al. Using basic fibroblast growth factor nanoliposome combined with ultrasound-introduced technology to early intervene the diabetic cardiomyopathy. Int J Nanomedicine. 2016;11:675–686.
   PubMed Web of Science ®Google Scholar
• Zhao YZ, Tian XQ, Zhang M, et al. Functional and pathological improvements of the hearts in diabetes model by the combined therapy of bFGF-loaded nanoparticles with ultrasound-targeted microbubble destruction. J Control Release. 2014;186:22–31.
   PubMed Web of Science ®Google Scholar
• Bardania H, Tarvirdipour S, Dorkoosh F. Liposome-targeted delivery for highly potent drugs. Artif Cells Nanomed Biotechnol. 2017;45:1478–1489.
   PubMed Web of Science ®Google Scholar
• Hong YJ, Pyo CG, Kim JC. Liposomes incorporating hydrophobically modified silk fibroin: pH-dependent release. Int J Biol Macromol. 2010;47:635–639.
   PubMed Web of Science ®Google Scholar
• Gokce EH, Korkmaz E, Tuncay-Tanrıverdi S, et al. A comparative evaluation of coenzyme Q10-loaded liposomes and solid lipid nanoparticles as dermal antioxidant carriers. Int J Nanomedicine. 2012;7:5109–5117.
   PubMed Web of Science ®Google Scholar
• Duvshani-Eshet M, Machluf M. Therapeutic ultrasound optimization for gene delivery: a key factor achieving nuclear DNA localization. J Control Release. 2005;108:513–528.
   PubMed Web of Science ®Google Scholar
• Koike H, Tomita N, Azuma H, et al. An efficient gene transfer method mediated by ultrasound and microbubbles into the kidney. J Gene Med. 2005;7:108–116.
   PubMed Web of Science ®Google Scholar
• Lan HY, Mu W, Tomita N, et al. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol. 2003;14:1535–1548.
   PubMed Web of Science ®Google Scholar
• Chappell JC, Song J, Burke CW, et al. Targeted delivery of nanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubble destruction for therapeutic arteriogenesis. Small. 2008;4:1769–1777.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ye C, Xu Y, et al. Ultrasound-mediated microbubble destruction increases renal interstitial capillary permeability in early diabetic nephropathy rats. Ultrasound Med Biol. 2014;40:1273–1281.
   PubMed Web of Science ®Google Scholar
• Yue T, Xu HL, Chen PP, et al. Combination of coenzyme Q10-loaded liposomes with ultrasound targeted microbubbles destruction (UTMD) for early theranostics of diabetic nephropathy. Int J Pharm. 2017;528:664–674.
   PubMed Web of Science ®Google Scholar
• Miller DL, Averkiou MA, Brayman AA, et al. Bioeffects considerations for diagnostic ultrasound contrast agents. J Ultrasound Med. 2008;27:611–632; quiz 633–636.
   PubMed Web of Science ®Google Scholar
• Jimenez C, de Gracia R, Aguilera A, et al. In situ kidney insonation with microbubble contrast agents does not cause renal tissue damage in a porcine model. J Ultrasound Med. 2008;27:1607–1615.
   PubMed Web of Science ®Google Scholar
• Kinns J, Aronson L, Hauptman J, et al. Contrast-enhanced ultrasound of the feline kidney. Vet Radiol Ultrasound. 2010;51:168–172.
   PubMed Web of Science ®Google Scholar
• Deelman LE, Declèves AE, Rychak JJ, et al. Targeted renal therapies through microbubbles and ultrasound. Adv Drug Deliv Rev. 2010;62:1369–1377.
   PubMed Web of Science ®Google Scholar
• Benozzi L, Cappelli G, Granito M, et al. Contrast-enhanced sonography in early kidney graft dysfunction. Transplant Proc. 2009;41:1214–1215.
   PubMed Web of Science ®Google Scholar
• Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther. 2012;30:49–59.
   PubMed Web of Science ®Google Scholar
• Chang JM, Kuo MC, Kuo HT, et al. Increased glomerular and extracellular malondialdehyde levels in patients and rats with diabetic nephropathy. J Lab Clin Med. 2005;146:210–215.
   PubMed Web of Science ®Google Scholar
• Noh SJ, Lee SH, Shin KY, et al. SP-8203 reduces oxidative stress via SOD activity and behavioral deficit in cerebral ischemia. Pharmacol Biochem Behav. 2011;98:150–154.
   PubMed Web of Science ®Google Scholar
• Loboda A, Sobczak M, Jozkowicz A, et al. TGF-β1/*Smads and miR-21 in renal fibrosis and inflammation. Mediators Inflamm. 2016;2016:8319283.
   PubMed Web of Science ®Google Scholar
• Fang XX, Sun GL, Zhou Y, et al. TGF-beta1 protection against Abeta1-42-induced hippocampal neuronal inflammation and apoptosis by TbetaR-I. Neuroreport. 2018;29:141–146.
   PubMed Web of Science ®Google Scholar
• Kveder R, Kajtna-Koselj M, Rott T, et al. Nephrotic syndrome in patients with diabetes mellitus is not always associated with diabetic nephropathy. Nephrol Dial Transplant. 2001;16(Suppl 6):86–87.
   PubMed Web of Science ®Google Scholar
• Wei K, Le E, Bin JP, et al. Quantification of renal blood flow with contrast-enhanced ultrasound. J Am Coll Cardiol. 2001;37:1135–1140.
   PubMed Web of Science ®Google Scholar
• Farina R, Pennisi F, La Rosa M, et al. Functional study of the transplanted kidney with power Doppler US and time/intensity curves. Radiol Med. 2007;112:64–73.
   PubMed Web of Science ®Google Scholar
• Dong Y, Wang WP, Lin P, et al. Assessment of renal perfusion with contrast-enhanced ultrasound: preliminary results in early diabetic nephropathies. Clin Hemorheol Microcirc. 2016;62:229–238.
   PubMed Web of Science ®Google Scholar
• Seyer-Hansen K. Renal hypertrophy in experimental diabetes mellitus. Kidney Int. 1983;23:643–646.
   PubMed Web of Science ®Google Scholar
• Parolini C, Noce A, Staffolani E, et al. Renal resistive index and long-term outcome in chronic nephropathies. Radiology. 2009;252:888–896.
   PubMed Web of Science ®Google Scholar
• Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci. 2013;124:139–152.
   PubMed Web of Science ®Google Scholar
• Chow F, Ozols E, Nikolic-Paterson DJ, et al. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 2004;65:116–128.
   PubMed Web of Science ®Google Scholar
• Ninichuk V, Khandoga AG, Segerer S, et al. The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. Am J Pathol. 2007;170:1267–1276.
   PubMed Web of Science ®Google Scholar
• Fornoni A, Ijaz A, Tejada T, et al. Role of inflammation in diabetic nephropathy. Curr Diabetes Rev. 2008;4:10–17.
   PubMedGoogle Scholar
• Choudhary N, Ahlawat RS. Interleukin-6 and C-reactive protein in pathogenesis of diabetic nephropathy: new evidence linking inflammation, glycemic control, and microalbuminuria. Iran J Kidney Dis. 2008;2:72–79.
   PubMedGoogle Scholar
• Lu J, Randell E, Han Y, et al. Increased plasma methylglyoxal level, inflammation, and vascular endothelial dysfunction in diabetic nephropathy. Clin Biochem. 2011;44:307–311.
   PubMed Web of Science ®Google Scholar
• Lee JM, Li J, Johnson DA, et al. Nrf2, a multi-organ protector? FASEB J. 2005;19:1061–1066.
   PubMed Web of Science ®Google Scholar
• Buckley BJ, Li S, Whorton AR. Keap1 modification and nuclear accumulation in response to S-nitrosocysteine. Free Radic Biol Med. 2008;44:692–698.
   PubMed Web of Science ®Google Scholar
• Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol. 2002;13:2600–2610.
   PubMed Web of Science ®Google Scholar
• Yang S, Zhang J, Wang S, et al. SOCS2 overexpression alleviates diabetic nephropathy in rats by inhibiting the TLR4/NF-kappaB pathway. Oncotarget. 2017;8:91185–91198.
   PubMedGoogle Scholar